How one reporter "fell down a data rabbit hole" while investigating how many Medicaid patients were denied costly hep C drugs, and what she'll do differently next time.
Calif.’s revised eligibility rules for new hep C drugs appear to be easing Medicaid patients’ access to the medications, yet the vast majority of Medicaid patients with hep C still aren't getting the costly drugs, state health officials say.
Jinah Choi is an assistant professor in the School of Natural Sciences at UC Merced. Her research focuses on the molecular characterization of hepatitis C virus (HCV) and its interactions with the host. HCV is an important human pathogen. More than 80 percent of HCV infection results in chronic infection that can lead to serious liver diseases, such as liver cirrhosis and hepatocellular carcinoma (i.e. liver cancer). Choi seeks to better understand HCV and its pathogenic mechanisms in order to develop a new and improved anti-HCV therapy. Choi received her Ph.D.
